Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 230-049-5 | CAS number: 6925-69-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data from J-check
Data source
Reference
- Reference Type:
- other: authoritative database
- Title:
- Repeated oral administration toxicity / reproductive developmental toxicity combined test using test material in rat
- Author:
- J-check
- Year:
- 2 010
- Bibliographic source:
- J-check, Environment Agency, Ministry of Health, Labour and Welfare,Ministry of Economy, Trade and Industry, and Ministry of the Environment, 2010
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: As mentioned below
- Principles of method if other than guideline:
- Repeated oral administration toxicity / reproductive developmental toxicity combined test using test material in rat.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Phthalimide
- EC Number:
- 201-603-3
- EC Name:
- Phthalimide
- Cas Number:
- 85-41-6
- Molecular formula:
- C8H5NO2
- IUPAC Name:
- 1H-isoindole-1,3(2H)-dione
- Details on test material:
- - Name of test material (as cited in study report):1H-isoindole-1,3(2H)-dione
- Molecular formula :C8H5NO2
- Molecular weight :147.133g/mol
- Substance type: Organic
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crj: CD (SD) IGS
- Details on test animals or test system and environmental conditions:
- Details on test animals and env. conditions
TEST ANIMALS
- Source: Charles River Japan Co., Ltd.
- Age at study initiation: 10week old
- Weight at study initiation: 371.7 g (350 to 402 g) for males
231.5 g (195 to 257 g) for female
- Fasting period before study:
- Housing: bracket type metal wire net floor cage.
- Use of restrainers for preventing ingestion (if dermal): yes/no
- Diet (e.g. ad libitum): CRF-1, Oriental Yeast Industry Co., Ltd, ad libitum
- Water (e.g. ad libitum): drinking water using tap water (Sapporo city) ad libitum
- Acclimation period:2 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 to 24 ° C
- Humidity (%):45 to 61%,
- Air changes (per hr): 10 to 15 times / hour
- Photoperiod (hrs dark / hrs light): 12 hours (lit from 8 am to 8 pm)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1 w / v% aqueous solution of sodium carmellose
- Details on exposure:
- Details on exposure
PREPARATION OF DOSING SOLUTIONS:
Test material suspended in a 1 w / v% aqueous solution of sodium carmellose
DIET PREPARATION
- Rate of preparation of diet (frequency):
- Mixing appropriate amounts with (Type of food):
- Storage temperature of food:
VEHICLE
- Justification for use and choice of vehicle (if other than water): 1 w / v% aqueous solution of sodium carmellose
- Concentration in vehicle: 0,250,500,1000 mg/kg bw/day
- Amount of vehicle (if gavage): 10ml/kg bw
- Lot/batch no. (if required):
- Purity: - Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: 14 days
- Proof of pregnancy: [vaginal plug / sperm in vaginal smear] referred to as [day 0 / day 1] of pregnancy:the day on which sperm was
confirmed in female vaginal plaque was taken as the 0th gestation
- After ... days of unsuccessful pairing replacement of first male by another male with proven fertility.:No data available
- Further matings after two unsuccessful attempts: [no / yes (explain)]No data available
- After successful mating each pregnant female was caged (how):No data available - Duration of treatment / exposure:
- Males:46
Females: 14 days before mating and the mating period until mating, and further the mating trial was the period of pregnancy and 3 days of gestation. - Frequency of treatment:
- Daily
- Duration of test:
- Approx 54 days
Doses / concentrations
- Remarks:
- 0,250,500,1000 mg/kg bw/day
- No. of animals per sex per dose:
- Total:96
0mg/kg bw/day:12 male and 12 female
250 mg/kg bw/day:12 male and 12 female
500 mg/kg bw/day:12 male and 12 female
1000mg/kg bw/day:12 male and 12 female - Control animals:
- yes, concurrent vehicle
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule:
- For all sexes, behaviours and appearance were observed by visual inspection and palpation at frequencies of once or more during the test period.
Parental animals observation and examinations
DETAILED CLINICAL OBSERVATIONS: Yes / No / No data
- Time schedule:
BODY WEIGHT: Yes
- Time schedule for examinations: On 1 day of administration (before administration), 2, 5, 7, 10 and 14 days of administration, after every 7 days (including the administration finish date) for males, for females 0, 1, , 7, 10, 14, 17, and 20, at 0, 1 and 4 days of nursing, and during the mating period
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Feed intake was measured for males except for the mating period, final administration day and autopsy date, and
for females on the same day as the body weight measurement day except for gestation day 0 and nursing 0 day,
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes / No / No data
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes / No / No data
- Time schedule for examinations: - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes:
- Skeletal examinations: Yes:
- Head examinations: No data - Statistics:
- Multiple sample χ ^ 2- test was performed on findings that showed one level of positive grade among sexual cycle, mating rate, conception rate, childbirth rate and nursing rate, and histopathological examination results, and in case of significant 2 Sample c 2 - Assay was performed. In addition, Fisher's direct probability test method was used when these tests failed. For other observations and findings showing positive grade of 2 or more out of the results of histopathological examination, after equality dispersal test of Bartlett, analyzed by one way analysis of variance or Kruskal-Wallis method, significant , The comparison group and the administration group were compared by Dunnett's test method or Mann-Whitney U-test method. For the test with the control group, the significance level was set at 5%.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, hair removal and crusts were observed in one patient in the 250 mg / kg group from 37 days to the autopsy date, but were accidental, not seen in other groups.
In females, no abnormality was observed in any of pre-pregnancy administration period, pregnancy period and nursing period. - Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No significant difference was observed between treated group and control group in any of period of male administration, female pre-pregnancy administration period, pregnancy period and nursing period.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- In males, low food intake was observed on day 46 of administration in the 500 mg / kg group, but it was a transient change with no dose correlation.
In females, there was no significant difference in treated administration group in each pregnancy administration period, pregnancy period and nursing period compared with the control group in each group. - Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, low food intake was observed on day 46 of administration in the 500 mg / kg group, but it was a transient change with no dose correlation.
In females, there was no significant difference in treated administration group in each pregnancy administration period, pregnancy period and nursing period compared with the control group in each group. - Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- There was no significant difference in any of the test items compared with the control group in each group of male
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, no significant difference was observed in each treated group and control group.
In the females, the high weight of the body weight ratio of the lung was in the 250 mg / kg group and the high value of the weight and weight ratio of the spleen was observed in the 500 mg / kg group, but in the 1000 mg /kg group compared with the control group There was no significant difference. - Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Histopathological examination revealed eosinophilic corpuscle of the proximal tubular epithelium in the kidney in males in 1 to 3 cases in the 250, 500 and 1000 mg / kg groups, but in comparison with the control group No significant difference was observed and it was not considered to be an effect of test material administration no dose-dependent increase was observed in the collection of lung foam cells and the number of occurrences of lymphocyte infiltration of the prostate, and the other findings were also changed only in one case, which is not related to test material administration. Histological examination of females showed only one case in the 1000 mg / kg group, but peripallal fatty liver in the liver, fatty degeneration of the proximal tubular epithelium in the kidney and atrophy of the thymus were observed in the kidney
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Maternal developmental toxicity
- Number of abortions:
- not specified
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not specified
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed - Changes in number of pregnant:
- no effects observed
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- There was no effect of test material administration on maternal necropsy, pregnancy period, number of corpus luteums, implantation number, implantation rate, birth rate, delivery rate, number of births and number of surviving children and birth rate at birth confirmation. However, in one case of the 1000 mg / kg group, among 9 males and 8 females, 1 male and 1 female died on 2 nursing, 2 male on 3 nursing and 1 male female on nursery 4.
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- 250 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- changes in number of pregnant
- clinical signs
- early or late resorptions
- food consumption and compound intake
- gross pathology
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- pre and post implantation loss
- total litter losses by resorption
- urinalysis
- Remarks on result:
- other: No toxic effects obaserved
Maternal abnormalities
- Abnormalities:
- not specified
- Localisation:
- not specified
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Compared with the control group, the low value of body weight of 4 days of nursing in males of the 500 mg / kg group, the 4 days of nursing of body weight gain, the weight gain and the body weight gain rate were low in females as compared with the control group. Even in the 1000 mg / kg group, low values of weight of body
weight of 4 days of nursing were observed in male, 4 days of body weight in nursing and low value of body weight gain were observed in females.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not specified - Reduction in number of live offspring:
- not specified
- Changes in sex ratio:
- not specified
- Changes in litter size and weights:
- not specified
- Changes in postnatal survival:
- no effects observed
- External malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- Deficits in the tail tips of the control group observed in general condition observation and one in each of the 1000 mg / kg group, and abdominal or cervical trauma in 1 case of each sex of 1000 mg / kg group were observed , No other abnormalities were found in any of the dead cases and autopsy of newborn sacrificed on the
4th day of nursing in any animals. - Skeletal malformations:
- not specified
- Visceral malformations:
- not specified
- Other effects:
- not specified
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 250 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- fetal/pup body weight changes
- changes in postnatal survival
- external malformations
- Remarks on result:
- other: No developmental toxic effects were observed
Fetal abnormalities
- Abnormalities:
- not specified
- Localisation:
- other: not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
- Treatment related:
- not specified
- Relation to maternal toxicity:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Any other information on results incl. tables
Influence of test material on reproductive performances of rats in combined repeat dose and reproductive/ developmental toxicity screening test
Item |
0mg/kg |
250mg/kg |
500mg/kg |
1000mg/kg |
No of animals examined |
12 |
12 |
12 |
12 |
No of pairs mated |
12 |
12 |
12 |
12 |
No of pairs with successful copulation |
12 |
12 |
12 |
12 |
Duration of mating (days. Mean ±SD.) |
3.3± 1.1 |
2.9 ±1.2 |
3.7± 3.4 |
3.6 ±2.5 |
Copulation index(%) |
100.0 |
100.0 |
100.0 |
100.0 |
No of pregnant animals |
12 |
12 |
12 |
10 |
Fertility index(%) |
100.0 |
100.0 |
100.0 |
83.3 |
a:(No. of pairs with successful copulation/ no. of pairs mated)x103
b:(No. of pregnant animals/ no. of pairs with successful copulation)x100
Influence of test material on developmental performances of rats in combined repeat dose and reproductive/ developmental toxicity screening test
Item |
0 mg/kg |
250mg/kg |
500 mg/kg |
1000 mg/kg |
No of pregnant animals |
12 |
12 |
12 |
12 |
No of corpora lutea |
16.9± 2.4 |
17.5± 2.8 |
17.7 ±2.1(11) |
18.1± 1.9 |
No of implantation sites |
15.7 ±1.7 |
16.6 ±1.7 |
15.7± 4.2 |
15.5± 3.2 |
Implantation index‘(%) |
93.3± 8.3 |
95.6 ±7.3 |
93.7 ±10.5 |
86.0 ±18.5 |
No of pups born |
14.3± 1.7 |
15.6± 2.1 |
14.3 ±5.2 |
15.2± 3.2 |
Delivery index"(%) |
91.2± 7.2 |
93.9 ±7.0 |
85.5± 27.3 |
98.2± 3.0** |
Live pups born |
|
|
|
|
No. |
14.3± 1.7 |
15.4 ±2.1 |
15.5 ±2.6(11) |
15.1 ±3.1 |
Live birth index‘(%) |
100.0± 0.0 |
98.9± 2.5 |
99.5± 1.6(11) |
99.4 ±1.8 |
Sex ratio (M/F) |
1.21 ±0.63 |
1.36± 0.64 |
1.10 ±0.82 |
1.23 ±0.57 |
Dead pups born |
|
|
|
|
No. |
0.0 ±0.0 |
0.2± 0.4 |
0.1± 0.3(11) |
0.1± 0.3 |
Gestation length(day) |
22.5± 0.5 |
22.7± 0.5 |
22.7 ±0.2(11) |
22.3 ±0.5 |
Gestation index‘(%) |
100.0 |
100.0 |
91.7 |
100.0 |
Nursing index°(%) |
100.0 |
100.0 |
100.0 |
100.0 |
Live pups on day 4 |
|
|
|
|
No |
14.1 ±1.4 |
15.3 ±2.1 |
15.0 ±2.4(11) |
14.1± 3.4 |
Viability index‘(%) |
99.0 ±2.3 |
99.5 ±1.8 |
97.3 ±5.0(11) |
91.1± 14.7 |
Body weight of pups(g) |
|
|
|
|
Male Day 0 |
6.93 ±0.40 |
6.82 ±0.69 |
6.71 ±0.50(11) |
6.41 ±0.62 |
Day 1 |
7.61 ±0.55 |
7.53± 0.91 |
7.24± 0.60(11) |
6.94 ±0.94 |
Day 4 |
10.88± 0.86 |
10.62± 1.55 |
10.04 ±0.83*(11) |
9.68 ±1.93* |
Day 04 gain(g) |
3.96 ±0.51 |
3.80 ±1.04 |
3.33 ±0.64(11) |
3.27± 1.54 |
Body weight gain% |
57.04± 5.54 |
55.48± 11.51 |
49.81± 10.29(11) |
50.441 ±22.95 |
Female Day 0 |
6.58 ±0.40 |
6.44± 0.64 |
6.27 ±0.49(11) |
6.09 ±0.56 |
Day 1 |
7.21± 0.47 |
7.06± 0.47 |
6.74± 0.59(11) |
6.58± 0.81 |
Day 4 |
10.43 ±0.79 |
10.08 ±1.46 |
9.39 ±0.65**(11) |
9.12± 1.71* |
Day 0-4. gain(g) |
3.85 ±0.47 |
3.63± 1.04 |
3.12± 0.46**(11) |
3.03 ±1.42* |
Body weight gain(%) |
58.50 ±5.70 |
56.26 ±13.16 |
50.03 ±8.93*(11) |
49.47± 22.16 |
Values are expressed as Mean ±S.D.
Values in parent theses are no. of animals examined.
Significantly different from 0 mg/kg group*p<0.05,**p <0.01
a:(No. of implantation sites/no. of corpora lutea)X100
b:(No of pups born/no. of implantation sites)X100
c:(No. or live pups born/ no. or pups born)X100
d:(No of females with live pups delivered/no. of pregnant females)X100
e:(No. of females nursing live pup/no. of females with normal delivery)X100
f: (No. of live pups on day 4/ no. of live pups born)X100
g:(Body weight gain/body weight on day 0)X100
Applicant's summary and conclusion
- Conclusions:
- The no effect level (NOEL) for reproduction of parent animals by repetitive oral administration of test material in this study was considered to be 1,000 mg / kg / day in male, 250 mg / kg / day for females, and 250 mg / kg / day for no effect on neonatal development (NOEL).
- Executive summary:
The reproductive and developmental toxicity of test material was performed on male and female rats. The test material suspended in 1 w / v% aqueous solution of sodium carmellose in dose concentration0, 250, 500, 1000 mg/kg bw/day and administered orally by gavage. The dose concentration were selected on the bases on dose finding study (5, 70 and 1000 mg / kg).Exposure to test material for the males, 46 days including the mating period and for the females for 14 days before mating and the mating period until mating, and further the mating trial was the period of pregnancy and 3 days of gestation. For males and females on 14th day of administration, they were allowed to live together in the same group within 1 to 1 (random combination) from the evening for only 14 days and the day on which sperm was confirmed in female vaginal plaque was taken as the 0th gestation. For all sexes, behaviours and appearance were observed by visual inspection and palpation at frequencies of once or more during the test period. For all female mated females, from the 21st day of pregnancy to the end of calving, the status of parturition, nursing behaviour, the number of total births, the number of surviving children and the number of dead children, the sex and the outer table of the infant were observed.
In males, hair removal and crusts were observed in one patient in the 250 mg / kg group from 37 days to the autopsy date, but were accidental, not seen in other groups. In females, no abnormality was observed in any of pre-pregnancy administration period, pregnancy period and nursing period.No significant difference was observed between treated group and control group in any of period of male administration, female pre-pregnancy administration period, pregnancy period and nursing period.In males, low food intake was observed on day 46 of administration in the 500 mg / kg group, but it was a transient change with no dose correlation. In females, there was no significant difference in treated administration group in each pregnancy administration period, pregnancy period and nursing period compared with the control group in each group.
In reproductive tests, male and female mating ratios, female sexual cycles and conception rates, test material administration in the necropsy, weight and histopathological examination of reproductive organs (testis, epididymis and ovaries) and endocrine organs (pituitary, adrenal) No effect was observed. On the other hand, pathological examination of the infertile reproductive organs of 2 cases observed in the 1000 mg / kg group showed no abnormality and no influence by test material administration was observed.
There was no effect of test material administration on maternal necropsy, pregnancy period, number of corpus luteums, implantation number, implantation rate, birth rate, delivery rate, number of births and number of surviving children and birth rate at birth confirmation. However, in one case of the 1000 mg / kg group, among 9 males and 8 females, 1 male and 1 female died on 2 nursing, 2 male on 3 nursing and 1 male female on nursery 4.Three cases were unknown, and the weight of surviving newborn infants was decreasing. In this mother animals, body weight loss and low food intake were also observed during the nursing period, and histopathological examination revealed peripallal fatty liver in the liver, fatty degeneration of the proximal tubular epithelium in the kidney and thymic Atrophy was observed. Therefore, although only one case appeared, the possibility that test material administration might have affected the mother's ability to nurture was considered.
In addition, in one case of 500 mg / kg group where delivery was not observed until 26th day of pregnancy, laparotomy of left and right uterus and cervix was observed at necropsy. In the same example, five implantation marks were seen by observation with the naked eye, both of which are considered to be early embryonic deaths, and the relation with test material administration was observed. survival were observed, in neonates weighing transition observed low values of body weight nursing 4 days in male and female 500 and 1000 mg / kg group, In addition, in the 500 mg / kg females, the body weight gain and the body weight gain rate were low, and even in females of the 1000 mg / kg group, the body weight gain was low. But neonatal weight during delivery was not changed in each group treated with test material. Therefore, a decrease or milk migration nursing ability of dams by test material administration was believed to have affected the newborn weighing 500 and 1000 mg / kg group, including one example of 1000 mg / kg group described above, The mechanism could not be clarifiedunder this test condition. Hence The no effect level (NOEL) for reproduction of parent animals by repetitive oral administration of test material in this study was considered to be 1,000 mg / kg / day in male, 250 mg / kg / day for females, and 250 mg / kg / day for no effect on neonatal development (NOEL).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
